| 2022年国家药品抽检中药饮片专项质量分析、标准修订和监管建议 |
| 投稿时间：2023-03-07 点此下载全文
|
| 引用本文：荆文光,程显隆,张萍,郭晓晗,李明华,杨建波,魏锋,马双成.2022年国家药品抽检中药饮片专项质量分析、标准修订和监管建议[J].中国现代中药,2023,25(12):2445-2452 |
| DOI：10.13313/j.issn.1673-4890.20230307006 |
| 摘要点击次数: 430 |
| 全文下载次数: 0 |
| 作者中文名 | 作者英文名 | 单位中文名 | 单位英文名 | E-Mail |
| 荆文光 |
JING Wen-guang |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 程显隆 |
CHENG Xian-long |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 张萍 |
ZHANG Ping |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 郭晓晗 |
GUO Xiao-han |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 李明华 |
LI Ming-hua |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 杨建波 |
YANG Jian-bo |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 魏锋* |
WEI Feng |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
| 马双成* |
MA Shuang-cheng |
中国食品药品检定研究院，北京 102629 |
National Institutes for Food and Drug Control, Beijing 102629, China |
|
|
|
| 中文摘要:国家药品监督管理部门组织全国开展中药饮片专项抽检，目的在于促进野生中药材资源的保护和种植的规范性，防控和化解中药饮片质量风险、强化中药饮片安全管理、保障中药饮片临床安全有效。2022年，国家药品抽检饮片专项包含艾叶、川牛膝、大黄、紫草、茜草、菊花、桃仁、金银花、片姜黄9个品种，抽样合计1679批，其中合格1623批，整体合格率为96.66%。借助这9个品种抽检数据的统计分析，结合探索性研究，对各品种法定标准和主要质量问题等进行总结与分析，提出未来标准修订和监管的建议，为全面推进中药饮片质量提升奠定基础。 |
| 中文关键词:中药饮片 抽检 质量分析 标准 监管 |
| |
| Quality Analysis, Standard Revision, and Regulatory Recommendations for Chinese Medicinal Decoction Pieces in the National Drug Sampling Inspection in 2022 |
|
|
| Abstract:The national medical products administrative department organized focused sampling inspections of Chinese medicinal decoction pieces. It aims to enhance protection and standardization in planting and cultivating wild Chinese herbal medicines, forestall, control, and defuse the quality risks of Chinese medicinal decoction pieces, strengthen safety management efforts of Chinese medicinal decoction pieces, and safeguard the safety and efficacy of their clinical applications. In 2022, 9 varieties of decoction pieces including Artemisiae Argyi Folium, Cyathulae Radix, and Rhei Radix et Rhizoma were sampling inspected, totaling 1679 batches, of which 1623 were qualified, and the overall qualification rate reached 96.66%. This paper summarized and analyzed the legal standards and main quality problems of each variety by the statistical analysis of 9 varieties of sampling data, combined with exploratory research. It proposed recommendations for standard revisions and regulation, laying the foundation for comprehensively promoting the quality of Chinese medicinal decoction pieces. |
| keywords:Chinese medicinal decoction pieces sampling inspection quality analysis standards supervision |
|
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|
